Shots:

• Chi-Med initiated the filing of NDA to the US FDA for surufatinib to treat pancreatic & non-pancreatic NET & plans to complete the NDA submission in the H1’21
• The NDA is based on two P-III studies that demonstrated a reduction in risk of progression or death by 67% & 51%- extending PFS of non-pancreatic NET & pancreatic NET patients with an acceptable risk/benefit ratio
• Surufatinib is an oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFR and FGFR. The US FDA has granted FTD to surufatinib for pancreatic and non-pancreatic NET in Apr’2020 and ODD for pancreatic NET in Nov’2019

­ Ref: PRNewswire | Image: Wikipedia